Compounded Tirzepatide

Active Ingredient in Mounjaro® and Zepbound®

AS LOW AS
$ 299 /month

Benefits

Reduces appetite and hunger

Slows stomach emptying and helps you feel fuller, longer

Helps control blood sugars

Program Summary

Initial Telehealth Visit
Real-time Virtual Support
Prescription + Medication
Remote Monthly Check-ins

What You Need To Know About Tirzepatide

  • What is Tirzepatide?

    Tirzepatide is the active ingredient in injectable weight-loss medication. It was FDA-approved in 2021 for Type 2 diabetes under the brand name Mounjaro® and later found to be beneficial for weight loss. It was FDA-approved in 2023 for weight loss as Zepbound®. Tirzepatide is the active ingredient in both Mounjaro® and Zepbound®.

  • How does Tirzepatide work?

    Tirzepatide mimics two naturally produced hormones in your body, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Its activity works to send signals to your brain to reduce hunger, slows down how quickly food leaves your stomach, and has hormonal effects to improve your metabolism. Together, these effects work to support weight loss.

  • What are the benefits of Tirzepatide?

    Tirzepatide has been observed to lead to weight loss of about 21%, with the weight loss being sustained. Health benefits associated with weight loss include improvements in energy, mood, and sleep, along with a reduction in heart disease, improvements in diabetes, blood sugar control, blood pressure control, cholesterol levels, kidney health, and fatty liver disease.

  • What are side effects I should be aware of?

    Side effects are typically mild and can include nausea, vomiting, diarrhea, and constipation. These side effects usually subside within 2-3 weeks, with nausea being considered an “on target” side effect that helps reduce your caloric intake.

    Less common but more serious side effects can include allergic reactions, low blood sugar, kidney problems (especially if you are very dehydrated), gallstones and pancreatitis. Thyroid tumors or cancer has been observed in rodents, but not yet humans.

  • Who should avoid Tirzepatide?

    You should avoid tirzepatide if any of the following conditions apply to you:

    • You are pregnant
    • You have an allergic reaction to tirzepatide or any of its ingredients
    • You have a personal or family history of medullary thyroid carcinoma
    • You have a personal or family history of multiple endocrine neoplasia syndrome type 2
  • How do I take Tirzepatide?

    Tirzepatide is injected under the skin either in the thigh, upper arm, or abdomen. Make sure you rotate the injection site each week. Tirzepatide can be taken with or without food, at any time of day. You should take the injection consistently on the same day each week. If you need to adjust the day of injection, try to avoid injecting within two days of a prior injection. When you forget a dose, make sure to take it within four days of the expected injection day.

  • What does the treatment plan generally look like?

    The standard, FDA-approved dosing schedule for tirzepatide is:

    • Month 1: 2.5 mg per week
    • Month 2: 5 mg per week
    • Month 3: 7.5 mg per week
    • Month 4: 10 mg per week
    • Month 5: 12.5 mg per week
    • Month 6: 15 mg per week

    Most patients start at the lowest dose in the first month, then steadily increase every month until you have found the right dose that fits your needs. 10 mg, 12.5 mg, and 15mg doses are considered maintenance doses.

  • What foods should I avoid?

    You are not expected to make strict dietary changes during the plan, but most patients naturally consume fewer calories.

    As constipation is a side effect to look out for, we recommend having a diet rich in fiber and drinking plenty of water, as doing so can minimize constipation.

  • Am I required to exercise?

    We recommend you to exercise while on tirzepatide, but it is not required. You may lose muscle mass while losing weight, and exercising regularly helps retain your muscle mass and fitness.

HOW DO GLP 1’s WORK?

The science behind GLP-1 Medications

When you eat, your digestive system releases the GLP-1 hormone. One of its jobs is to tell your body to produce insulin, which reduces your blood sugar levels. High levels of GLP-1 reduces your appetite and makes you feel full.

GLP-1 medications mimic the GLP-1 hormone. Semaglutide and tirzepatide both mimic this body response, leading to a less hunger, a feeling of fullness. These conditions work together to help patients lose weight.

Real People, Real Results

Get inspired by hearing some of our clients’ success stories

After struggling with weight loss for years, Sarah tried Lumimed GLP-1 Semaglutide. Within just a few months, she lost 20 pounds and felt more energized and confident. The medication helped her control her appetite, making it easier to eat smaller portions while still feeling satisfied. Now, Sarah is enjoying a healthier lifestyle, and Lumimed GLP-1 Semaglutide was the key to her success.

ANGELA G.

Was very professional and answered all my questions I am a senior citizen and he made feel confident that I was in good hands and didn’t have to be concerned that I was being taken advantage of.

JOSEPH D.

The prescription arrived less than a week after purchasing. I took my first shot when I received it. The next day I am not hungry. I feel full. I can’t wait to see how weight loss works.

CAEL C.

The convenience and the coaching support are wonderful. I love that the meds were tailored to me, not just oh let’s try this. I would recommend to anyone struggling with weight loss.

GIBSON H.

The doctors have been responsive to my questions and concerns. My coach Ashley has been instrumental in my journey. She celebrates with me, challenges and encourages me.

JAYLON E.

Love this plan . Down 17.7 lbs in 9 weeks. Prescription is easy to understand and administer. No side effects so far. Would definitely recommend to anyone struggling with weight loss.

ELIOT B.

I was scared in the beginning be once I started my experience with the coaches my determination I'm reaching my goals.

  1. ‍ Surmount 1 trial - Jastreboff et al (2022) Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine
  2. Step 1 trial - Wilding et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine
We Are LegitScript Certified!

LegitScript only works with organizations that have ensured patients receive the highest quality of care.